Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs SoundHound AI Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.69 (market cap $39.89B), while SoundHound AI Inc trades at $6.59 (market cap $2.89B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 13.8× SoundHound AI Inc's market cap. Which is the better fit depends on your goals.
| ALNY | SOUN | |
|---|---|---|
Market Cap | $39.89B | $2.89B |
Sector | Health | Technology |
52-Week High | $491.22 | $21.40 |
52-Week Low | $278.09 | $5.90 |
Enterprise Value | $38.15B | $2.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SOUN trades at $6.64, down 0.6% on the day, with a bearish technical signal driven by moving averages. The company shows strong revenue growth but significant losses, with a net income margin of -91.84% in 2026. Recent news highlights expansion in voice AI and the planned LivePerson acquisition, yet investor caution persists due to cash burn and execution risks. Analyst consensus remains bullish with a $13.00 price target, but the stock faces pressure from high valuation multiples and negative profitability metrics.
The outlook for SOUN hinges on scaling its AI platform to achieve profitability, supported by enterprise adoption and strategic deals. Investment opportunity lies in its growth trajectory and market position in voice AI, but risks include sustained losses, competitive pressures, and reliance on financing. Investors should weigh the high upside potential against substantial operational and financial risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
